APELLIS PHARMACEUTICALS INC (APLS) Stock Price, Forecast & Analysis
USA - NASDAQ:APLS - US03753U1060 - Common Stock
APLS Key Statistics, Chart & Performance
The current stock price of APLS is 19.64 USD. In the past month the price decreased by -15.72%. In the past year, price decreased by -25.73%.
APLS Latest News, Press Relases and Analysis
APLS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.28 | 405.25B | ||
| AMGN | AMGEN INC | 15.55 | 183.03B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.80B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.83 | 110.51B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.24 | 72.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 887.37 | 59.32B | ||
| INSM | INSMED INC | N/A | 40.71B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 9.56 | 23.46B | ||
| INCY | INCYTE CORP | 16.8 | 21.07B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.43 | 20.80B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.13 | 14.56B |
Related stock screener links
About APLS
Company Profile
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. The company is headquartered in Waltham, Massachusetts and currently employs 705 full-time employees. The company went IPO on 2017-11-09. The firm is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
Company Info
APELLIS PHARMACEUTICALS INC
100 Fifth Avenue
Waltham MASSACHUSETTS 02451 US
CEO: Cedric Francois
Employees: 705
Phone: 16179775700
APELLIS PHARMACEUTICALS INC / APLS FAQ
Can you describe the business of APELLIS PHARMACEUTICALS INC?
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. The company is headquartered in Waltham, Massachusetts and currently employs 705 full-time employees. The company went IPO on 2017-11-09. The firm is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
Can you provide the latest stock price for APELLIS PHARMACEUTICALS INC?
The current stock price of APLS is 19.64 USD. The price increased by 0.67% in the last trading session.
Does APLS stock pay dividends?
APLS does not pay a dividend.
How is the ChartMill rating for APELLIS PHARMACEUTICALS INC?
APLS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
How is the market expecting APLS stock to perform?
27 analysts have analysed APLS and the average price target is 38.7 USD. This implies a price increase of 97.06% is expected in the next year compared to the current price of 19.64.
What sector and industry does APELLIS PHARMACEUTICALS INC belong to?
APELLIS PHARMACEUTICALS INC (APLS) operates in the Health Care sector and the Biotechnology industry.
What is APELLIS PHARMACEUTICALS INC worth?
APELLIS PHARMACEUTICALS INC (APLS) has a market capitalization of 2.48B USD. This makes APLS a Mid Cap stock.
APLS Technical Analysis
APLS Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to APLS. APLS has only an average score on both its financial health and profitability.
APLS Financial Highlights
Over the last trailing twelve months APLS reported a non-GAAP Earnings per Share(EPS) of 0.31. The EPS increased by 116.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 4.43% | ||
| ROA | 4.25% | ||
| ROE | 11.21% | ||
| Debt/Equity | 0.9 |
APLS Forecast & Estimates
27 analysts have analysed APLS and the average price target is 38.7 USD. This implies a price increase of 97.06% is expected in the next year compared to the current price of 19.64.
For the next year, analysts expect an EPS growth of 98.32% and a revenue growth 25.24% for APLS